Skip to main content

Ban Randy's Form 4 filing

Inspire Medical Systems, Inc.INSP · filed Feb 18, 2025

Accession no.
0001104659-25-014860
Filed
Feb 18, 2025
Trade date
Feb 9-13, 2025
Filing delay
9 daysLate
Rule 10b5-1 plan
Checked

This filing lists 13 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.69M. It was filed 9 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ban RandyCIK 0001737127Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 9, 2025Common StockFTax withholdingDisposed−314$182.15−$57,195.12,767Direct
Feb 13, 2025Common StockAGrant or awardAcquired+5,076$0.00$07,843Direct
Feb 13, 2025Common StockMOption exerciseAcquired+25,000$67.63+$1,690,75032,843Direct
Feb 13, 2025Common StockSSaleDisposed−2,500$178.54F5−$446,35030,343Direct
Feb 13, 2025Common StockSSaleDisposed−1,000$179.41F6−$179,41029,343Direct
Feb 13, 2025Common StockSSaleDisposed−1,330$180.79F7−$240,450.728,013Direct
Feb 13, 2025Common StockSSaleDisposed−3,770$181.90F8−$685,76324,243Direct
Feb 13, 2025Common StockSSaleDisposed−3,242$182.90F9−$592,961.821,001Direct
Feb 13, 2025Common StockSSaleDisposed−2,541$183.79F10−$467,010.3918,460Direct
Feb 13, 2025Common StockSSaleDisposed−3,452$184.81F11−$637,964.1215,008Direct
Feb 13, 2025Common StockSSaleDisposed−3,824$185.84F12−$710,652.1611,184Direct
Feb 13, 2025Common StockSSaleDisposed−3,341$186.96F13−$624,633.367,843Direct
Feb 13, 2025Common StockSSaleDisposed−584$187.66−$109,593.447,259Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 13, 2025Common StockMOption exerciseDisposed−25,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.08 to $178.93. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.12 to $179.75. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.29 to $181.27. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.30 to $182.26. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.30 to $183.27. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.31 to $184.30. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F11

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $184.33 to $185.31. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F12

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.35 to $186.32. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F13

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.35 to $187.29. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

Executive Vice President, Patient Access and Therapy Development

Read the full filing on SEC EDGAR (opens in a new tab)